ヴァーガス神経刺激は,mtDNA/cGAS-STING/NLRP3炎症体軸経由でトラウマ性脳損傷における認知障害を緩和する
Bingkai Ren1,2, Junwei Kang1, Xiaoyang Dong1
1Department of Rehabilitation, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Neurocritical care
|September 4, 2025
まとめ
ヴァガス神経刺激 (VNS) は,ミトコンドリア DNA/cGAS/STING/NLRP3経路による神経炎症を軽減することによって,脳外傷 (TBI) の後の認知機能を改善します. この神経保護効果は,サイクロスポリンA治療で確認された.
科学分野:
- 神経科学
- 免疫学
- 細胞生物学
背景:
- トラウマ性脳損傷 (TBI) は重大な認知障害を引き起こす.
- ヴァガス神経刺激 (VNS) は炎症反射を調節し,神経変性疾患において有望である.
- TBIに関連した認知障害に対するVNSの可能性は,ほとんど未知のままです.
研究 の 目的:
- TBIのラットモデルにおける認知障害の改善におけるVNSの有効性を調査する.
- ミトコンドリアDNA/cGAS/STING/NLRP3の炎症経路に焦点を当てて,基礎となる分子メカニズムを解明する.
- VNSの神経保護効果と主要な炎症媒介体との相互作用を評価する.
主な方法:
- ネズミは制御された皮質インパクト (TBIモデル) 前にVNSのインプラントを施した.
- 評価には,行動テスト (モリス水迷路),組織学的分析,ウエスタン・ブロッティング,qPCR,ミトコンドリア膜ポテンシャルの測定が含まれていた.
- 介入には,鼻内または腹腔内でのサイクロスポリンA (CsA) とSTINGアゴニスト (2' 3'- cGAMP) の投与が含まれていた.
主要な成果:
- VNSはTBIのネズミの認知機能を著しく改善し,海馬の神経損傷を逆転させた.
- VNSはcGAS- STING経路を弱め,NLRP3炎症体の活性化を抑制し,ミトコンドリア膜の潜在力を増加させた.
- STINGアゴニストはVNSの有益な効果を無効化し,CsAはcGAS- STING,NLRP3炎症体,および熱死を抑制することで神経保護を示した.
結論:
- ネズミのTBIモデルでは,バゴス神経の刺激により,熱死と神経炎症が効果的に軽減されます.
- このメカニズムは,ミトコンドリアDNA/cGAS/STING/NLRP3シグナル伝達経路の調節を伴う.
- VNSはTBI後の認知機能障害の治療戦略として有望です
関連する概念動画
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:28Traumatic Brain Injury l: Introduction
25
DefinitionTraumatic brain injury, or TBI, is a disturbance of normal brain function induced by an external mechanical force, such as a direct blow to the head or a penetrating injury. It can affect both brain structure and function, producing a wide range of clinical outcomes. TBI is a heterogeneous condition, meaning its effects may differ based on the type, location, and severity of the injury.Basis of ClassificationTBI is classified based on severity, injury mechanism, or pathophysiology. In...
25
01:22Cerebral Edema ll: Pathophysiology
19
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
19
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35